Lycia Therapeutics (LYCA)

Lycia Therapeutics on one page: daily short volume, large holders and insider trades. Listed on Nasdaq.

Download CSV

44.3%

Short share of volume

2026-11-03

$38.3M

Insider flow, 90 days

11 buys, 0 sells

As of 2026-11-03.

Daily short volume

FINRA Reg SHO, the last 8 sessions. JSON

As of 3 November 2026, the short share of LYCA volume is 44.3%, up 10.8 points over the last five sessions. Over the last 8 readings it ranged from 26.5% (23 October 2026) to 48.5% (29 October 2026). The latest reading is 5.1 points above the 8-session average of 39.1%, on 88K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-03	39K	88K	44.3%	0
2026-11-02	53K	128K	41.6%	0
2026-10-30	42K	96K	43.8%	0
2026-10-29	36K	75K	48.5%	0
2026-10-28	97K	267K	36.4%	1,855
2026-10-27	68K	203K	33.5%	2,437
2026-10-26	218K	569K	38.3%	1,724
2026-10-23	313K	1.2M	26.5%	74

Insider trades

SEC Form 4, newest first. JSON

Insiders at LYCA reported 11 open-market buys worth $38.3M in the last 90 days and no open-market sells. Latest filing: Venrock Healthcare Capital Partners III, L.P. (10% owner) on 2026-10-30.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-10-30	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	200	$26.86	$5K	6.9M
2026-10-30	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	9K	$26.27	$231K	6.9M
2026-10-29	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	1K	$26.33	$26K	6.8M
2026-10-28	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	4K	$25.97	$115K	6.8M
2026-10-28	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	11K	$25.23	$267K	6.8M
2026-10-27	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	31K	$26.84	$834K	6.8M
2026-10-27	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	9K	$25.84	$226K	6.8M
2026-10-26	Versant Ventures VII GP, L.P.	10% owner	Conversion	1.4M	price not stated in the filing	not stated	1.4M
2026-10-26	Versant Ventures VII GP, L.P.	10% owner	Conversion	5.6M	price not stated in the filing	not stated	5.6M
2026-10-26	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	8K	$26.97	$223K	6.8M
2026-10-26	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	1.9M	$18.00	$35.0M	6.8M
2026-10-26	Venrock Healthcare Capital Partners III, L.P.	10% owner	Conversion	4.8M	price not stated in the filing	not stated	4.8M
2026-10-23	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	28K	$26.11	$741K	53K
2026-10-23	Venrock Healthcare Capital Partners III, L.P.	10% owner	Buy	25K	$25.68	$631K	25K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

9 holders report 5% or more of LYCA in their latest filing, all on Schedule 13G (passive). The largest reported stake is Nimish Shah at 11.9% of the class (6,850,237 shares), filed 2026-10-30 for an event on 2026-10-23.

Filed	Form	Holder	Shares	Of class	Event
2026-10-30	13G	Nimish Shahindividual	6.9M	11.9%	2026-10-23
2026-10-30	13G	Bong Y. Kohindividual	6.9M	11.9%	2026-10-23
2026-10-30	13G	VHCP Management XP, LLCother entity	6.9M	11.9%	2026-10-23
2026-10-30	13G	Venrock Healthcare Capital Partners XP, L.P.partnership	6.9M	11.9%	2026-10-23
2026-10-30	13G	VHCP Management EG, LLCother entity	6.9M	11.9%	2026-10-23
2026-10-30	13G	VHCP Management III, LLCother entity	6.9M	11.9%	2026-10-23
2026-10-30	13G	Venrock Healthcare Capital Partners EG, L.P.partnership	6.9M	11.9%	2026-10-23
2026-10-30	13G	VHCP Co-Investment Holdings III, LLCother entity	6.9M	11.9%	2026-10-23
2026-10-30	13G	Venrock Healthcare Capital Partners III, L.P.partnership	6.9M	11.9%	2026-10-23

What this page is

Lycia Therapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Lycia Therapeutics (LYCA), SEC CIK 1806540, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-30.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-30.JSON and CSV
Company record: EDGAR filing index for CIK 1806540Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Datasets

Frequently Asked Questions

How much of LYCA is sold short?

FINRA has not reported a short position for LYCA at the latest settlement.

What is LYCA's daily short volume?

On 2026-11-03, 38,850 of the 87,796 LYCA shares reported to FINRA were sold short, 44.3% of the day's reported volume. Short volume is a flow for one day, not a position.

Does LYCA have fails to deliver?

LYCA does not appear in the SEC fails-to-deliver files on record.

Are LYCA insiders buying or selling?